Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Biodeal Pharma Expands Injectable Manufacturing with Biological E Facility Acquisition
    5 October 2026

    Biodeal Pharma Expands Injectable Manufacturing with Biological E Facility Acquisition

    Biodeal Pharmaceuticals Limited has strengthened its sterile injectable manufacturing and CDMO capabilities by acquiring a manufacturing facility of Biological E. Limited at Paonta Sahib in Himachal Pradesh.

    The acquisition is part of Biodeal’s broader strategy to expand its pharmaceutical contract development and manufacturing capabilities and build a stronger presence in regulated international markets. The acquired manufacturing facility spans approximately 14 acres and has an annual production capacity of around 135 million units.

  • CERVAVAC Enters WHO-Qualified Vaccine List, Opening Door to Global HPV Vaccine Procurement
    5 October 2026
    CERVAVAC Enters WHO-Qualified Vaccine List, Opening Door to Global HPV Vaccine Procurement
    Indias indigenous quadrivalent Human Papillomavirus (HPV) vaccine CERVAVAC, manufactured by Serum Institute of India Pvt. Ltd., has received WHO prequalification, marking a significant milestone for India’s HPV vaccine programme and its potential global reach.
  • Sun Pharma Presents Two-Year LEQSELVI Data at EADV 2026, Showing Sustained Hair Regrowth in Severe Alopecia Areata
    5 October 2026
    Sun Pharma Presents Two-Year LEQSELVI Data at EADV 2026, Showing Sustained Hair Regrowth in Severe Alopecia Areata

    Sun Pharmaceutical Industries Limited has announced new long-term data for LEQSELVI® (deuruxolitinib) in adults with severe alopecia areata at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. The company said LEQSELVI was featured in seven presentations, including data from a European open-label extension study evaluating treatment for up to two years.

  • India Clears 41 Pharma & MedTech Innovation Projects with ₹1,600 Crore Support
    2 October 2026
    India Clears 41 Pharma & MedTech Innovation Projects with ₹1,600 Crore Support
    The Government of India has approved financial assistance of around ₹1,600 crore for 41 pharmaceutical and medical technology projects under the first round of the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) initiative.
  • FDA Approves First Heart Valve Designed to Grow with Children
    2 October 2026
    FDA Approves First Heart Valve Designed to Grow with Children
    The U.S. Food and Drug Administration today approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease. This innovative device may reduce the need for repeat open-heart surgeries in children with heart defects, reflecting the Trump Administration’s commitment to bringing breakthrough medical technologies to market as quickly and safely as possible.
  • Scandinavian Phase 3 Trial Finds Aspirin Does Not Prevent Colorectal Cancer Recurrence After Liver Metastasis Treatment
    2 October 2026
    Scandinavian Phase 3 Trial Finds Aspirin Does Not Prevent Colorectal Cancer Recurrence After Liver Metastasis Treatment
    A large Scandinavian phase 3 clinical trial has found that starting aspirin after curative-intent treatment for colorectal cancer that has spread to the liver does not reduce the risk of cancer recurrence or death. The findings come from the ASAC trial, conducted across hospitals in Norway, Sweden and Denmark.
  • FDA Flags Major GMP Violations at Fresenius Kabi Sterile Injectable Facility; Recalls and Corrective Actions Under Review
    2 October 2026
    FDA Flags Major GMP Violations at Fresenius Kabi Sterile Injectable Facility; Recalls and Corrective Actions Under Review
    The U.S. Food and Drug Administration (FDA) has issued a warning letter to Fresenius Kabi USA LLC over significant Current Good Manufacturing Practice (CGMP) violations identified at the company's sterile drug manufacturing facility in Melrose Park, Illinois.
  • MSD’s Tulisokibart Hits Key Endpoints in Phase 2b HS Study
    1 October 2026
    MSD’s Tulisokibart Hits Key Endpoints in Phase 2b HS Study
    MSD announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS).
  • Jagsonpal Pharmaceuticals to Acquire Group Pharma’s Wellness Portfolio in ₹46.7 Crore Deal
    30 September 2026
    Jagsonpal Pharmaceuticals to Acquire Group Pharma’s Wellness Portfolio in ₹46.7 Crore Deal

    Jagsonpal Pharmaceuticals Limited has entered into a Business Transfer Agreement (BTA) with Group Pharmaceuticals Limited to acquire its Wellness Portfolio, in a transaction that could have a total consideration of up to ₹46.7 crore.

    According to the company’s regulatory disclosure dated September 23, 2026, the acquisition will be undertaken on a going-concern basis through a slump sale. Jagsonpal said the move is aimed at strengthening its pharmaceutical portfolio, expanding its presence across relevant therapeutic segments and increasing its market reach.

  • Foundayo Shows Greater Weight Loss and A1C Reduction Than Oral Semaglutide
    30 September 2026
    Foundayo Shows Greater Weight Loss and A1C Reduction Than Oral Semaglutide
    Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes.
Subscribe to Pharma News